|Title:||Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin||Authors:||YU-YUN SHAO
|Issue Date:||2010||Journal Volume:||40||Journal Issue:||4||Start page/Pages:||286-293||Source:||Japanese Journal of Clinical Oncology||Abstract:||
Objective: We studied tau and excision repair cross-complementing 1 expression to evaluate their predictive values in advanced breast carcinoma patients. Methods: Patients treated with paclitaxel and cisplatin as the first-line chemotherapy for locally advanced or metastatic breast cancer were enrolled. The expression levels of tau and excision repair cross-complementing 1 were assessed by immunohistochemistry and examined for their associations with treatment response and survival. Results: Fifty-four patients were included in this study. Despite the strong association between tau expression and lower histological grade and estrogen receptor expression, tau expression remained an independent predictor for a lower response rate in multivariate analysis (odd ratio = 0.24, P = 0.02). However, tau expression was a predictor for longer overall survival in both univariate analysis (median, 57.5 vs. 30.4 months, P = 0.02) and multivariate analysis (hazard ratio = 0.36, P = 0.008). Excision repair cross-complementing 1 was not associated with treatment response or overall survival. Conclusions: Tau expression but not excision repair cross-complementing 1 in advanced breast cancer predicts poor response to combination chemotherapy of paclitaxel and cisplatin. However, tau expression is significantly associated with longer overall survival. ? The Author (2010). Published by Oxford University Press. All rights reserved.
|ISSN:||0368-2811||DOI:||10.1093/jjco/hyp184||SDG/Keyword:||cisplatin; estrogen receptor; excision repair cross complementing protein 1; hormone; paclitaxel; progesterone receptor; tau protein; antineoplastic agent; cisplatin; DNA binding protein; endonuclease; ERCC1 protein, human; paclitaxel; tau protein; tumor marker; adjuvant therapy; adult; advanced cancer; aged; article; breast carcinoma; cancer adjuvant therapy; cancer combination chemotherapy; cancer grading; clear cell carcinoma; drug dose regimen; drug dose sequence; gene expression; human; immunohistochemistry; low drug dose; major clinical study; mucinous carcinoma; multiple cycle treatment; overall survival; prediction; prognosis; survival time; treatment response; biosynthesis; breast tumor; disease free survival; drug resistance; female; genetics; Kaplan Meier method; metabolism; middle aged; phase 2 clinical trial; retrospective study; treatment outcome; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials, Phase II as Topic; Disease-Free Survival; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Female; Humans; Immunohistochemistry; Kaplan-Meiers Estimate; Middle Aged; Paclitaxel; Prognosis; Retrospective Studies; tau Proteins; Treatment Outcome; Tumor Markers, Biological
|Appears in Collections:||病理學科所|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.